PIT 565
Alternative Names: PIT-565Latest Information Update: 24 Jun 2025
At a glance
- Originator Novartis Pharmaceuticals
- Class Antineoplastics; Immunotherapies; Trispecific antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Non-Hodgkin's lymphoma; Precursor B-cell lymphoblastic leukaemia-lymphoma; Systemic lupus erythematosus
Most Recent Events
- 19 Jun 2025 Novartis plans a phase Ib trial for Rheumatoid Arthritis (RA), in July 2025 (SC) (NCT07029555)
- 31 Oct 2024 Phase-I clinical trials in Systemic lupus erythematosus (Treatment-experienced) in Spain (SC) (NCT06335979)
- 28 Mar 2024 Novartis Pharmaceuticals plans a phase Ib trial for Systemic lupus erythematosus (Treatment-experienced) (SC) (NCT06335979)